Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Geron Corp (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9978
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Geron is headquartered in Menlo Park, California, the US.

Geron Corp (GERN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Geron Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 12
Equity Offering 13
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 13
Geron to Raise up to USD100 Million in Public Offering of Shares 14
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 15
Geron Completes Public Offering Of Shares For US$103.5 Million 16
Geron Announces Public Offering Of Shares For Up To US$50 Million 18
Asset Transactions 19
BioTime Completes Acquisition Of Stem Cell Assets From Geron 19
Geron Corp – Key Competitors 21
Geron Corp – Key Employees 22
Geron Corp – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 01, 2018: Geron reports third quarter 2018 financial results and recent company events 24
Jul 31, 2018: Geron Reports Second Quarter 2018 Financial Results and Recent Company Events 26
May 10, 2018: Geron Reports First Quarter 2018 Financial Results 28
Mar 16, 2018: Geron Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events 29
Nov 01, 2017: Geron Reports Third Quarter 2017 Financial Results 31
Aug 09, 2017: Geron Reports Second Quarter 2017 Financial Results 32
May 09, 2017: Geron Reports First Quarter 2017 Financial Results and Recent Events 33
Mar 01, 2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results 35
Product News 37
12/12/2017: Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting 37
11/01/2017: Janssen to Present Abstracts on Imetelstat at ASH 2017 39
06/18/2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress 41
05/17/2018: Geron Announces Oral Presentation at European Hematology Association Congress 43
Clinical Trials 44
Nov 20, 2017: Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes 44
Oct 31, 2017: Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes 45
Jul 31, 2017: Geron Announces Updates to Imetelstat Clinical Development 46
Apr 10, 2017: Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen 47
Apr 05, 2017: Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Geron Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Geron Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 10
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 12
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 13
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 14
Geron to Raise up to USD100 Million in Public Offering of Shares 15
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 16
Geron Completes Public Offering Of Shares For US$103.5 Million 17
Geron Announces Public Offering Of Shares For Up To US$50 Million 19
BioTime Completes Acquisition Of Stem Cell Assets From Geron 20
Geron Corp, Key Competitors 22
Geron Corp, Key Employees 23

List of Figures
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Bank of Canada:企業のM&A・事業提携・投資動向
    National Bank of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's National Bank of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Ventana Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Ventana Medical Systems Inc (VMS), a subsidiary of F. Hoffmann-La Roche Ltd is a manufacturer of tissue-based diagnostic solutions for healthcare market. The company develops cancer diagnostic solutions for breast pathology, cervical diagnostics, colorectal pathology, special stains, lung pa …
  • Banco ABC Brasil SA (ABCB4):企業の財務・戦略的SWOT分析
    Banco ABC Brasil SA (ABCB4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Oman Cables Industry SAOG (OCAI):企業の財務・戦略的SWOT分析
    Oman Cables Industry SAOG (OCAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • OHB SE:企業の戦略・SWOT・財務情報
    OHB SE - Strategy, SWOT and Corporate Finance Report Summary OHB SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Sports Direct International Plc:企業の戦略・SWOT・財務情報
    Sports Direct International Plc - Strategy, SWOT and Corporate Finance Report Summary Sports Direct International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • UCB SA (UCB)-製薬・医療分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • AutoGenomics Inc-医療機器分野:企業M&A・提携分析
    Summary AutoGenomics Inc (AutoGenomics) is a provider of automated technologies for test processes inherent in genetic analysis. The company offers infiniti systems and FDA cleared products and RUO products. Its infiniti system is designed for processing AutoGenomics' unique proprietary BioFilmChip …
  • HDFC Bank Ltd:戦略・SWOT・企業財務分析
    HDFC Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary HDFC Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Hedberg Landscape & Masonry Supplies:企業の戦略的SWOT分析
    Hedberg Landscape & Masonry Supplies - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • ELITechGroup Inc-医療機器分野:企業M&A・提携分析
    Summary ELITechGroup Inc (ELITech) is a medical device company that manufactures and distributes in vitro diagnostic equipment and reagents. The company’s products portfolio includes clinical chemistry, cytology, hematology, immunology, microbiology and molecular diagnostics. Its clinical chemistry …
  • Becton Dickinson and Co (BDX)-製薬・医療分野:企業M&A・提携分析
    Summary Becton Dickinson and Co (BD) is a medical technology company that manufactures and sells medical devices, reagents and instrument. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management …
  • Tenaska Inc-エネルギー分野:企業M&A・提携分析
    Summary Tenaska, Inc. (Tenaska) is an independent energy company that develops, designs, finances, and manages and operates non-utility power plants. It purchases and sells natural gas, electric capacity, energy, and renewable energy products; acquires, manages, and optimizes natural gas, and electr …
  • SciClone Pharmaceuticals Inc:企業の戦略的SWOT分析
    SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Ortivus AB (ORTI B):企業の財務・戦略的SWOT分析
    Summary Ortivus AB (Ortivus) is a supplier of mobile solutions for emergency medical care. The company develops and offers cardiology, and mobile monitoring and communication solutions. Its products portfolio comprises ortivus mobiMed software, ortivus M531 measuring unit, ortivus PM1-1 patient unit …
  • Energy Transfer Partners, L.P.:戦略・SWOT・企業財務分析
    Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hikal Ltd (HIKAL):企業の財務・戦略的SWOT分析
    Summary Hikal Ltd (Hikal) is a pharmaceutical company that provides custom manufacturing; active ingredients and intermediates. The company provides product portfolio such as antiepileptic, antihistamine, antipsychotic and antilipemic, among others. It offers services such as custom synthesis, contr …
  • Rakuten Inc (4755):企業の財務・戦略的SWOT分析
    Rakuten Inc (4755) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Aridis Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aridis Pharmaceuticals Inc (Aridis) is a biopharmaceutical companythat focusses on development of novel, differentiated therapies for infectious diseases. The company’s pipeline product uses disruptive platform technology to discover potent human monoclonal antibodies from patients.Its propr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆